Back to results
US 11,304,978 B2Granted
Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
AssigneePact Pharma, Inc.
InventorsBarbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
Life of this patent
Estimating the term…
Abstract
Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
Claims24
A composition comprising a peripheral T cell comprising:
- a. an exogenous T cell receptor (TCR) recognizing a neoantigen;
- and
- b. an exogenous CD8 comprising:
- i. a CD8α signal peptide, a CD8α extracellular domain, a CD8α transmembrane domain, and a CD8β intracellular domain;
- or
- ii. a CD8α signal peptide, a CD8α extracellular domain, a CD8α transmembrane domain, and a CD4 intracellular domain.
3 more elements
A composition comprising a peripheral T cell comprising:
- a. an exogenous T cell receptor (TCR) recognizes a neoantigen;
- and
- b. an exogenous CD8 comprising:
- i. a CD8α signal peptide, a CD8α extracellular domain, a CD8α transmembrane domain, and a CD8β intracellular domain;
- or
- ii. a CD8α signal peptide, a CD8α extracellular domain, a CD8α transmembrane domain, and a CD4 intracellular domain;
- wherein the exogenous TCR is encoded by a polynucleotide integrated into a TRAC and/or TRBC locus of the cell.
4 more elements
Dependencies are inferred from the claim text.